Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

Figure 3

Overall survival. A median OS was not reached in either group. A 5 yr OS of 62% versus 60% in the treatment versus the control group was observed.